A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma

摘要: Background: Best response rates have been achieved with three-drug regimens containing 5-FU in the treatment of advanced gastric cancer (AGC) and oral fluoropyrimidines are best alternatives as substitutes for infusional 5-FU. This study aimed to evaluate safety toxicity epirubicin, cisplatin, UFT (ECU regimen) AGC outpatients. Materials methods: Forty-one patients received plus leucovorin. Epirubicin 50 mg/m 2 cisplatin 60mg/m were administered on Day 1. Three hundreds (300) /day was leucovorin at a fixed dose 90 mg/day 21 days, followed by 7-day rest period. Cycles repeated every 4 weeks. Performance status either 0 1. Results: Among 41 enrolled, complete partial 7.3% 36.6% patients, respectively, an overall rate 43.9%. Stable disease observed 34.1% 22% showed progression. Median time progression 5.2 months median survival 12.3 months. A cycles (range: 1-6) chemotherapy administered. The main grade III-IV toxicities nausea/vomiting (19.4%) neutropenia (12.1%). Grade IV perforation renal failure. Conclusion: ECU appears be effective regimen AGC, acceptable tolerability manageable toxicity. In regimens, substitution offers possibility increased outpatient compliance.